Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

Pas encore traduit Pas encore traduit
Auteurs
Catégorie Primary study
Registry of Trialsclinicaltrials.gov
Year 2008

This article is not included in any systematic review

This article is part of the following publication threads:
Loading references information
This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in individuals with atrial fibrillation. Patients will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, \& Warfarin. The expected duration of the study is 24 months.
Epistemonikos ID: 2a7e2461249af70803c04ba690fd13427f69f73e
First added on: Aug 10, 2015